Protagonist Therapeutics is a U.S.-incorporated biotechnology company pursuing the discovery and development of disulfide-rich peptides (DRPs) as well differentiated alternatives to biologics, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which ideal small molecule and/or biologic options are unavailable. DRPs are a proven chemical class of drugs with numerous examples of orally stable and injectable NCEs on the market and in various stages of clinical development. The company has a validated technology platform well suited to explore the full potential of the DRP scaffold class. It comprises of a purposefully built computational design environment, directed evolution approaches to prepare millions of molecules via phage libraries, and classical small molecule medicinal chemistry-type analoging and SAR development.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
06/04/13 | $14,000,000 | Series B |
Johnson & Johnson Innovation Starfish Ventures | undisclosed |
09/19/13 | $4,000,000 | Series B-2 |
Pharmstandard International | undisclosed |